Title:
化合物及びその製造方法並びに用途
Document Type and Number:
Japanese Patent JP7318956
Kind Code:
B2
Abstract:
The present disclosure provides a compound of formula I or a pharmaceutically acceptable salt, a solvate, or a prodrug thereof, wherein M is a monovalent alkali metal. The present disclosure also provides a method for preparing the compound or its pharmaceutically acceptable salt, solvate, or prodrug, and further provides a pharmaceutical composition containing the compound and its use in the preparation of a medicine, which can be used for the treatment of CCR4-mediated diseases.
Inventors:
Cho, Hai Phong
Application Number:
JP2020558674A
Publication Date:
August 01, 2023
Filing Date:
January 11, 2019
Export Citation:
Assignee:
Medspring International Limited
International Classes:
C07D409/12; A61K31/416; A61P1/00; A61P11/00; A61P11/02; A61P11/06; A61P15/00; A61P17/00; A61P17/06; A61P19/00; A61P19/02; A61P19/06; A61P19/10; A61P21/00; A61P27/02; A61P31/12; A61P31/16; A61P37/02; A61P37/08; A61P43/00
Domestic Patent References:
| JP2012518673A |
Other References:
Procopiou, Panayiotis A. et al,Synthesis and Structure-Activity Relationships of Indazole Arylsulfonamides as Allosteric CC-Chemokine Receptor 4 (CCR4) Antagonists,Journal of Medicinal Chemistry,2013年,Vol.56(5),p.1946-1960
Procopiou, Panayiotis A. et al,Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation,Bioorganic & Medicinal Chemistry Letters,2012年,Vol.22(8),p.2730-2733
Miah, Afjal H. et al,Identification of pyrazolopyrimidine arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists,Bioorganic & Medicinal Chemistry,2017年,Vol.25(20),p.5327-5340
Procopiou, Panayiotis A. et al,Lead optimisation of the N1 substituent of a novel series of indazole arylsulfonamides as CCR4 antagonists and identification of a candidate for clinical investigation,Bioorganic & Medicinal Chemistry Letters,2012年,Vol.22(8),p.2730-2733
Miah, Afjal H. et al,Identification of pyrazolopyrimidine arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists,Bioorganic & Medicinal Chemistry,2017年,Vol.25(20),p.5327-5340
Attorney, Agent or Firm:
Taro Yaguchi